Current Status of Canakinumab Biosimilars
No canakinumab biosimilars are approved worldwide as of late 2024. Canakinumab (Novartis's Ilaris) faces multiple barriers, including active patents and regulatory hurdles for complex monoclonal antibodies. Development is underway by several companies, but none have reached market.[1]
Key Patents and Expiry Dates
Novartis holds patents on canakinumab through at least 2032 in the US (e.g., composition-of-matter patent US 7,829,093 expires 2029, with formulation and method patents extending further). In Europe, key patents expire around 2030-2034. Check DrugPatentWatch.com for the latest US patent landscape, including challenges: DrugPatentWatch: Canakinumab Patents.[2][3]
| Region | Key Patent Expiry | Notes |
|--------|-------------------|-------|
| US | 2029-2034 | Multiple Orange Book listings; Paragraph IV challenges possible post-2029 |
| EU | 2030-2033 | Supplementary protection certificates extend some |
| Japan | 2031 | Similar to EU timeline |
Biosimilars typically launch 1-2 years after patent expiry if litigation resolves favorably.
Companies Developing Biosimilars
- Celltrion (South Korea): Leads with CT-P47 in Phase 3 trials (completed enrollment 2023). Targets US/EU approval by 2026-2027; comparable efficacy/safety to Ilaris shown in interim data.
- Samsung Bioepis: Phase 3 ongoing (SB15); FDA filing expected 2025.
- Alvotech/Bio-Thera: Early Phase 3; aims for 2027 launch.
- Intas/Momenta (China/US): Preclinical to Phase 1; lower priority markets first.
- Others (e.g., Formycon, Intas): Phase 1/2 stages.
At least 5-7 programs in pipeline, but Celltrion is closest to submission.[4][5]
Regulatory Timelines and Approvals
EMA and FDA require Phase 3 comparability studies for biosimilars. Celltrion's CT-P47 could file with EMA in 2025 (post-Phase 3 readout), with approval 6-12 months later if successful—potentially available 2026 in Europe. US FDA approval might slip to 2027 due to patent thicket. No Japanese approvals yet; PMDA review could align with EU.[6]
Factors delaying progress:
- Complex IL-2/IL-1β targeting requires extensive PK/PD similarity data.
- Ongoing Novartis patent enforcement (e.g., suits against adalimumab biosimilars as precedent).
Comparison to Other IL Inhibitors
Unlike adalimumab (biosimilars launched 2023 post-2023 patent expiry), canakinumab's newer profile delays entry. Similar to secukinumab (Cosentyx), where first biosimilars are filing in 2025 despite 2030+ patents—litigation will decide speed.[7]
| Drug | First Biosimilar Expected | Status |
|-------------------|---------------------------|-------------------------|
| Canakinumab | 2026-2028 (EU/US) | Phase 3 ongoing |
| Secukinumab | 2026-2027 | Phase 3 filings soon |
| Adalimumab | Already available | Multiple approved |
Pricing and Market Impact
Ilaris lists at $1,400-$6,000 per dose (US). Biosimilars could cut costs 20-40% initially, rising to 70%+ with competition—easing access for rare autoinflammatory diseases like CAPS or TRAPS. Novartis revenue ($1B+ annually) faces threat post-2030.[8]
Patient and Clinical Considerations
Used off-label in cardiovascular trials (e.g., CANTOS), biosimilars must prove non-inferiority in rare disease populations. Injection-site reactions (most common side effect) match originators in trials. No major immunogenicity signals reported yet.9
Sources
[1]: FDA Purple Book (biosimilars list, no canakinumab entries)
[2]: DrugPatentWatch.com - Ilaris Patent Expiration
[3]: EPO Register - Canakinumab Patents
[4]: Celltrion Pipeline Update (Q3 2024)
[5]: Samsung Bioepis Investor Report
[6]: EMA Biosimilar Guidelines; FDA Interchangeability Standards
[7]: Novartis SEC Filings (patent disputes)
[8]: IQVIA Market Data